MX2017014991A - Beta-caseina a2 y su capacidad antioxidante. - Google Patents
Beta-caseina a2 y su capacidad antioxidante.Info
- Publication number
- MX2017014991A MX2017014991A MX2017014991A MX2017014991A MX2017014991A MX 2017014991 A MX2017014991 A MX 2017014991A MX 2017014991 A MX2017014991 A MX 2017014991A MX 2017014991 A MX2017014991 A MX 2017014991A MX 2017014991 A MX2017014991 A MX 2017014991A
- Authority
- MX
- Mexico
- Prior art keywords
- beta
- animal
- casein
- disease
- antioxidant capacity
- Prior art date
Links
- 102000011632 Caseins Human genes 0.000 title abstract 4
- 108010076119 Caseins Proteins 0.000 title abstract 4
- 235000021247 β-casein Nutrition 0.000 title abstract 4
- 239000003963 antioxidant agent Substances 0.000 title abstract 2
- 230000003078 antioxidant effect Effects 0.000 title abstract 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 abstract 2
- 230000001737 promoting effect Effects 0.000 abstract 2
- RKYJTDSQXOMDAD-JKXTZXEVSA-N (2s,3s)-2-[[(2s)-1-[2-[[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1N(C(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CC=2C=CC(O)=CC=2)CCC1 RKYJTDSQXOMDAD-JKXTZXEVSA-N 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 201000003883 Cystic fibrosis Diseases 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 108010024636 Glutathione Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 201000002772 Kwashiorkor Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000008425 Protein deficiency Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 206010044688 Trisomy 21 Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 108010020546 beta-casomorphin 7 Proteins 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000006862 enzymatic digestion Effects 0.000 abstract 1
- 230000035558 fertility Effects 0.000 abstract 1
- 229960003180 glutathione Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- 230000001590 oxidative effect Effects 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
Abstract
Mejora de la capacidad antioxidante en un animal aumentando el nivel de glutatión en la sangre o tejido del animal que comprende proporcionar una composición que contiene beta-caseína al animal para el consumo, donde la beta-caseína comprende al menos 75% en peso de una o más beta-caseínas que no pueden producir beta-casomorfina-7 en la digestión enzimática. Los usos incluyen como oxidante, para tratar o prevenir los síntomas de cáncer, inflamación, kwashiorkor (deficiencia de proteína), convulsiones, autismo, síndrome de Down, síndrome de fatiga crónica, enfermedad de Alzheimer, enfermedad de Parkinson, anemia de células falciformes, enfermedad hepática, fibrosis quística, VIH, SIDA, infección, ataque cardíaco, apoplejía y diabetes, evitando o reduciendo los efectos del envejecimiento, promoviendo la recuperación de tejido después del ejercicio físico y promoviendo la fertilidad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562165854P | 2015-05-22 | 2015-05-22 | |
| PCT/NZ2016/050081 WO2016190750A1 (en) | 2015-05-22 | 2016-05-20 | Beta-casein a2 and antioxidant capacity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017014991A true MX2017014991A (es) | 2018-04-10 |
Family
ID=57394138
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017014991A MX2017014991A (es) | 2015-05-22 | 2016-05-20 | Beta-caseina a2 y su capacidad antioxidante. |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10702580B2 (es) |
| EP (1) | EP3297643A4 (es) |
| JP (1) | JP7137745B2 (es) |
| KR (1) | KR102374024B1 (es) |
| CN (1) | CN107708711A (es) |
| AU (2) | AU2016267960B2 (es) |
| BR (1) | BR112017024975B1 (es) |
| CA (1) | CA2986889C (es) |
| CL (1) | CL2017002967A1 (es) |
| HK (1) | HK1250631A1 (es) |
| IL (1) | IL255725B (es) |
| MX (1) | MX2017014991A (es) |
| MY (1) | MY190600A (es) |
| PH (1) | PH12017550132A1 (es) |
| RU (1) | RU2751945C9 (es) |
| WO (1) | WO2016190750A1 (es) |
| ZA (1) | ZA201707968B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102471621B1 (ko) * | 2016-03-30 | 2022-11-25 | 디 에이2 밀크 컴퍼니 리미티드 | 베타-카세인 및 인지 기능 |
| CA3036494C (en) * | 2016-09-30 | 2022-10-18 | The A2 Milk Company Limited | Beta-caseins and gut microbiota |
| CN115553340A (zh) * | 2022-10-18 | 2023-01-03 | 北大荒完达山乳业股份有限公司 | 一种具有提高免疫力功能的降敏牛奶及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU691362B2 (en) | 1994-11-04 | 1998-05-14 | New Zealand Dairy Board | Method of selecting non-diabetogenic milk or milk products and milk or milk products so selected |
| AU723396B2 (en) | 1995-05-16 | 2000-08-24 | Corran Norman Stuart Mclachlan | Food product and process |
| RU2157233C1 (ru) * | 1999-05-11 | 2000-10-10 | Санкт-Петербургская общественная организация "Институт биорегуляции и геронтологии" | Тетрапептид, обладающий геропротекторной активностью, фармакологическое средство на его основе и способ его применения |
| WO2002019832A1 (en) | 2000-09-08 | 2002-03-14 | New Zealand Dairy Board | MILK CONTAINING β-CASEIN WITH PROLINE AT POSITION 67 DOES NOT AGGRAVATE NEUROLOGICAL DISORDERS |
| US20060280802A1 (en) * | 2002-10-04 | 2006-12-14 | Campbell Julie H | Therapeutic uses of beta-casein a2 and dietary supplement containing beta-casein a2 |
| RU2280448C2 (ru) * | 2002-11-10 | 2006-07-27 | Институт биофизики клетки РАН | Композиция с антиоксидантными свойствами и способ лечения болезней млекопитающих |
| EP1718163A1 (en) * | 2004-02-23 | 2006-11-08 | The Texas A&M University System | Antioxidant compositions and methods of use thereof |
| US20060105972A1 (en) * | 2004-11-17 | 2006-05-18 | Nagasawa Herbert T | Method to enhance delivery of glutathione and ATP levels in cells |
| EP2448958A4 (en) * | 2009-06-01 | 2013-11-06 | Kenneth James Friel | PEPTIDES OF HUMAN MILK |
| CN104159592B (zh) * | 2012-03-09 | 2018-10-19 | 方塔拉合作集团有限公司 | 酪蛋白组合物的用途 |
| SG10201709509RA (en) * | 2013-05-31 | 2017-12-28 | A2 Milk Co Ltd | Beta-Casein A2 And Prevention Of Inflammation Of The Bowel |
| CA2912871A1 (en) * | 2013-05-31 | 2014-12-04 | Edison Pharmaceuticals, Inc. | Carboxylic acid derivatives for treatment of oxidative stress disorders |
| JP6436592B2 (ja) * | 2013-07-12 | 2018-12-12 | ズィ・エイツー・ミルク・カンパニー・リミテッド | ベータカゼインａ２およびラクトース不耐性の症状の低減または予防 |
| WO2015026245A1 (en) | 2013-08-23 | 2015-02-26 | The A2 Milk Company Limited | Beta-casein a2 and blood glucose levels |
-
2016
- 2016-05-20 US US15/576,012 patent/US10702580B2/en active Active
- 2016-05-20 JP JP2018513263A patent/JP7137745B2/ja active Active
- 2016-05-20 EP EP16800366.3A patent/EP3297643A4/en active Pending
- 2016-05-20 CA CA2986889A patent/CA2986889C/en active Active
- 2016-05-20 CN CN201680032032.7A patent/CN107708711A/zh active Pending
- 2016-05-20 MX MX2017014991A patent/MX2017014991A/es unknown
- 2016-05-20 AU AU2016267960A patent/AU2016267960B2/en active Active
- 2016-05-20 RU RU2017142002A patent/RU2751945C9/ru active
- 2016-05-20 MY MYPI2017704402A patent/MY190600A/en unknown
- 2016-05-20 WO PCT/NZ2016/050081 patent/WO2016190750A1/en active Application Filing
- 2016-05-20 BR BR112017024975-8A patent/BR112017024975B1/pt active IP Right Grant
- 2016-05-20 KR KR1020177036927A patent/KR102374024B1/ko active IP Right Grant
-
2017
- 2017-11-16 IL IL255725A patent/IL255725B/en unknown
- 2017-11-19 PH PH12017550132A patent/PH12017550132A1/en unknown
- 2017-11-22 CL CL2017002967A patent/CL2017002967A1/es unknown
- 2017-11-23 ZA ZA201707968A patent/ZA201707968B/en unknown
-
2018
- 2018-08-03 HK HK18110018.7A patent/HK1250631A1/zh unknown
-
2022
- 2022-07-04 AU AU2022204759A patent/AU2022204759A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12017550132A1 (en) | 2018-05-07 |
| RU2751945C9 (ru) | 2021-12-21 |
| JP7137745B2 (ja) | 2022-09-15 |
| IL255725B (en) | 2021-10-31 |
| EP3297643A4 (en) | 2019-02-06 |
| IL255725A (en) | 2018-01-31 |
| CA2986889C (en) | 2023-08-29 |
| ZA201707968B (en) | 2019-10-30 |
| AU2022204759A1 (en) | 2022-07-28 |
| JP2018514236A (ja) | 2018-06-07 |
| KR102374024B1 (ko) | 2022-03-11 |
| CN107708711A (zh) | 2018-02-16 |
| CA2986889A1 (en) | 2016-12-01 |
| KR20180010251A (ko) | 2018-01-30 |
| CL2017002967A1 (es) | 2018-06-01 |
| US10702580B2 (en) | 2020-07-07 |
| AU2016267960B2 (en) | 2022-04-07 |
| BR112017024975B1 (pt) | 2022-03-15 |
| RU2017142002A3 (es) | 2019-11-21 |
| MY190600A (en) | 2022-04-27 |
| WO2016190750A1 (en) | 2016-12-01 |
| AU2016267960A1 (en) | 2017-12-14 |
| EP3297643A1 (en) | 2018-03-28 |
| RU2017142002A (ru) | 2019-06-24 |
| BR112017024975A2 (pt) | 2018-08-07 |
| US20180169186A1 (en) | 2018-06-21 |
| HK1250631A1 (zh) | 2019-01-11 |
| RU2751945C2 (ru) | 2021-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500767A1 (en) | Pharmaceutical composition, methods for treating and uses thereof | |
| PH12017550132A1 (en) | Beta-casein a2 and antioxidant capacity | |
| BR112014027227A2 (pt) | modificação alvejada de malato desidrogenase | |
| TR201901110T4 (tr) | Empagliflozinin terapötik kullanımları. | |
| TN2014000236A1 (en) | Use of chemically modified heparin derivates in sickle cell disease | |
| EP3792280A3 (en) | Anti-blys antibody | |
| UA95105C2 (ru) | Применение производного лактамида для снижения токсичности в препарате, который может соприкасаться с кожей или глазами человека или животного, производные лактамида и способы их получения | |
| FR2969495B1 (fr) | Extrait de parties aeriennes de maca riche en polyphenols et composition le comprenant | |
| ZA201504103B (en) | Organ and tissue preservation formulations with increased stability and shelf life | |
| WO2015023553A3 (en) | Modulation of disease by administration of sulfur-containing, amino acid-specific small molecules | |
| WO2018093830A3 (en) | Method and composition for crude formulations of fortified sugar for glycemic control | |
| BR112015004012A2 (pt) | combinações de inibidores de sglt 2 e fármacos anti-hipertensivos | |
| PH12014501579A1 (en) | Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers | |
| WO2020106876A3 (en) | Compositions and methods for increasing fetal hemoglobin and treating sickle cell disease | |
| EA201391063A1 (ru) | Аполипопротеин a-iv в качестве антидиабетического пептида | |
| WO2009012785A3 (en) | Complexes of an emulgator and a fatty acid | |
| WO2014031586A3 (en) | Methods for treating cardiovascular diseases | |
| RU2008132752A (ru) | Способ консервативного лечения лейкоплакии (плоскоклеточной метаплазии) мочевого пузыря | |
| PH12015502657B1 (en) | Interactions of betanodaviruses in infection | |
| WO2020206115A3 (en) | Angptl2 antisense oligonucleotides and uses thereof | |
| WO2013188876A3 (en) | Methods for modulating kallikrein (klkb1) expression | |
| TH177458A (th) | เบต้า-คาเซอิน a2 และความสามารถในการต้านอนุมูลอิสระ | |
| BR112015008753A2 (pt) | tratamento de depressão e ptsd | |
| 李振营 | A Comparison between American Individualism and Chinese Collectivism-From the View of Cherishing Life in War | |
| WO2012173781A3 (en) | Methods of treating glucose metabolism disorders |